Bloodworks

Pavel Davizon-Castillo

29 Jun 2024, reporter.nih.gov

NCT03787927

Phase 1/2, Status unknown, 2018, 60 people, 27 Dec 2018, clinicaltrials.gov

NCT01808521

Early phase 1, Completed, 2013, 3 people, 11 Mar 2013, clinicaltrials.gov

NCT01800526

Phase 1/2, Completed, 2013, 21 people, 27 Feb 2013, clinicaltrials.gov

National Heart, Lung, and Blood Institute

K99, Inflammation-mediated platelet hyperreactivity and thrombosis, K99HL156058, US$210.7k, 2021–2025, 29 Jun 2024, reporter.nih.gov